SWAN is pleased to announce an investment in AGED Diagnostics, which is using genomic innovation to develop the most accurate blood test for liver disease to help physicians keep patients in the monitoring program, reduce the financial burden for health insurers, and improve patient outcomes through early detection and intervention.
AGED tools can differentiate benign from advanced liver disease and simultaneously stage fibrosis (liver scarring). Their technology uses a targeted genomic sequencing assessment to measure the concentration of target biomarkers (genetic signatures) in circulation. The presence of biomarkers past a defined concentration indicates a diagnosis of liver disease (NASH) and/or fibrosis.